Topic:

Clinical Trials

Latest Headlines

Latest Headlines

Receptos shares spike as oral drug reduces brain lesions in PhII MS trial

Last year Receptos pulled off one of the most successful biotech IPOs in a red-hot market for new offerings, largely on the promise of a midstage study underway for its oral multiple sclerosis drug. And this morning investors spurred a 35% spike in its share price as investigators spelled out promising data from that Phase II trial.

Eli Lilly gets on the trial transparency bandwagon

In keeping with changing industry standards, Eli Lilly has joined the host of drugmakers opening up their data vaults, going further than some but not quite baring it all.

Amgen is gunning for approval of viral cancer vaccine, adds positive combo data

CHICAGO--Amgen's big Phase III effort on the viral cancer vaccine talimogene laherparepvec may have fallen just shy of hitting the mark for a key metric on overall survival, but after hitting the primary goal on durable response rates for patients with melanoma, the big biotech says it plans to move ahead and seek an approval to start selling the treatment. And investigators here at ASCO have also begun to add some new data to back up its potential as a combination cancer therapy.

Lilly's ramucirumab scores a marginal gain for lung cancer patients

Eli Lilly wrestled its way into the spotlight at ASCO Saturday morning with evidence that its cancer drug ramucirumab delivers a marginal benefit for patients suffering from advanced non-small cell lung cancer. And analysts quickly heralded the data, saying it should help pave the way to quickly broaden the market for this drug.

AbbVie's leukemia drug program continues to wow analysts in early study

AbbVie's experimental leukemia drug ABT-199 is continuing to wow analysts with some stellar early-stage data. At the interim point of a Phase Ib study, ABT-199/GDC-0199 combined with rituximab registered an 84% overall response rate among patients with chronic lymphocytic leukemia.

UPDATED: Clovis preps for a blockbuster showdown with AstraZeneca

Clovis Oncology has come out of the gate at ASCO with updated--and promising--data on its targeted lung cancer drug CO-1686, offering fresh evidence of its durability and effectiveness.

Roche partners with Roche on 'breakthrough' PD-L1 cancer program

Today, Roche put out the word that their PD-L1 drug MPDL3280A won the FDA's coveted breakthrough therapy designation, potentially putting it on an inside track at the agency, which has been hurrying along new medicines in the pipeline.

PhIII flop for top Boston cancer stem cell program batters Dainippon Sumitomo

Over the long holiday weekend, Dainippon Sumitomo's shares took a beating--dropping 21% at one point, according to Bloomberg--as investors reacted to the news that BBI608 proved to be a dud in its most advanced trial for colorectal cancer.

Isis surges on promising head-to-head thrombosis drug study

Shares of Isis Pharmaceuticals surged 9% this morning as the Carlsbad, CA-based antisense drug developer posted positive outcomes for a head-to-head Phase II study comparing ISIS-FXIRx with Lovenox on thrombosis. The biotech says the top 300 mg dose of its therapy beat out the widely used anticoagulant, lowering the number of blood clots while reducing the number of bleeding incidents.

Novartis, Boehringer vie for COPD market share with combo meds

Rivals Novartis and Boehringer Ingelheim are touting positive results for their combination COPD treatments, duking it out with GlaxoSmithKline for dominance of a market that could reach $14 billion by 2018.